Mometasone Furoate Anhydrous is a glucocorticoid or corticosteroid used topically to reduce inflammation of the skin (itching dermatoses) or in the airways (Asthma).
Sterling holds Certificate of Suitability n. R0-CEP 2006-301-Rev 03 issued by Quality of Medicines & HealthCare (EDQM) on 21/09/2009.
US DMF was submitted to FDA on 16/06/2003 and the following number was assigned n. 16648.
Drug product containing Sterling’s Mometasone Furoate Anhydrous is commercialized in Europe, USA and other Countries.
Warning: Invalid argument supplied for foreach() in /srv/users/serverpilot/apps/sterling2019/public/wp-content/themes/sterling/single.php on line 64